Aflibercept approval expands treatment options for patients with ROP

Article

Prof Anat Loewenstein, Chair, Department of Ophthalmology, Tel Aviv Medical Center (Israel), comments on the significance of the US FDA approval of aflibercept for preterm infants with retinopathy.

Sheryl Stevenson, Group Editorial Director, Ophthalmology Times Europe®: What is the importance or significance of this approval for these patients?

Prof Anat Loewenstein, Chair, Department of Ophthalmology, Tel Aviv Medical Center (Israel): I think that the approval of aflibercept for premature infants with ROP is a very significant step forward in the management of these little patients of ours.

We know that many of them have uncontrollable disease. Not all of them respond to bevacizumab and the ability of us to be able to treat them with a registered drug, FDA approved, will enhance the way we manage them.

We have good treatment with anti-VEGF therapy for ROP patients and having a registered good drug to do it with...with the results that we are seeing...is of huge benefit to these patients.

Stevenson: Thank you for your insights. Always very appreciated.

Loewenstein: Thank you.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.